Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) EBITDA (2022 - 2025)

Envoy Medical's EBITDA history spans 4 years, with the latest figure at -$6.5 million for Q3 2025.

  • For Q3 2025, EBITDA fell 8.76% year-over-year to -$6.5 million; the TTM value through Sep 2025 reached -$21.7 million, down 3.03%, while the annual FY2024 figure was -$19.3 million, 35.65% up from the prior year.
  • EBITDA for Q3 2025 was -$6.5 million at Envoy Medical, down from -$5.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.6 million in Q3 2023 and bottomed at -$13.3 million in Q1 2023.
  • The 4-year median for EBITDA is -$5.0 million (2025), against an average of -$5.5 million.
  • The largest YoY upside for EBITDA was 216.39% in 2023 against a maximum downside of 1369.67% in 2023.
  • A 4-year view of EBITDA shows it stood at -$11.5 million in 2022, then soared by 57.35% to -$4.9 million in 2023, then rose by 7.11% to -$4.5 million in 2024, then plummeted by 42.51% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's EBITDA are -$6.5 million (Q3 2025), -$5.7 million (Q2 2025), and -$5.0 million (Q1 2025).